Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in Salvage Malignant Mesothelioma
NCT02293005Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2015
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in malignant mesothelioma, sponsored by University of Texas MD Anderson Cancer Center. Started May 2015; status: completed.
02
Drugs
alisertib
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT02293005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293005.